<mfqc class="mjywxh"></mfqc>
J9国际站 J9
About Us
Corporate Profile
Management Team
Milestones
Our Vision
Affiliates
CTTQ Akesobio
Akeso Pharma
AD Pharmaceuticals
Contact Us
R&D and science
Technology Platform
Products Center
R&D and Manufacturing
Expanded Access Policy
Collaborations
Investor Relations
Financial Reports
Presentations
IR Monthly Reports
Announcements and Circulars
Corporate Governance
IR Calendar
IR Contact
Media
Akeso News
Media Coverage V2
Career
Social Recruitment
Campus Recruitment
简
|
EN
|
2025-07-28
NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
2025-07-16
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
2025-07-03
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
2025-06-16
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
2025-06-05
Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations—Third Approved Indication for Cadonilimab
2025-05-08
WSJ | Her Unusual Path to CEO and Finding a Cancer Drug
2025-04-28
INVITATION | Akeso, lnc.BUSINESS UPADATE CALL
2025-04-26
Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
2025-04-25
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
2025-04-23
Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy
2025-04-18
Akeso’s Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
2025-03-31
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
«
1
2
3
4
5
6
7
8
9
»
